M&T Bank’s Krystal Biotech KRYS Stock Holding History

M&T Bank’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,785	Closed	-$520K	–	1553
2025 Q2	$520K	Buy	3,785 +85	+2%	+$12.5K	﹤0.01%	1061
2025 Q1	$667K	Buy	+3,700	New	+$622K	﹤0.01%	960

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

M&T Bank's KRYS Position: Q3 2025 in Review

M&T Bank sold out of Krystal Biotech (KRYS) in Q3 2025, closing a stake of 3,785 shares — an estimated $520K sold.

M&T Bank first reported a position in KRYS in Q1 2025 and held it in 2 quarters. The position peaked at $667K in Q1 2025. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

M&T Bank reported no remaining Krystal Biotech position as of Q3 2025 after selling out during the quarter.
M&T Bank sold 3,785 Krystal Biotech shares in Q3 2025, an estimated $520K.
M&T Bank first reported a position in Krystal Biotech in Q1 2025 and held it in 2 quarters.
M&T Bank's Krystal Biotech position peaked at $667K in Q1 2025.
284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on M&T Bank's 13F filing for Q3 2025, filed 14 Nov 2025.